Semaglutide
medicationA GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.
Survodutide is a peptide that is research only, not approved for human use in the US.
Also known as BI 456906
Survodutide is being developed by Boehringer Ingelheim and Zealand Pharma for obesity and metabolic liver disease. It remains an investigational medicine, despite RUO versions appearing online.

Not approved for human use in the US. We list it so you can learn what it is, but we do not link to anyone selling it. Not FDA-approved. It is available for human use only through authorized clinical research.
As of September 28, 2026.
Randomized human trials show biological and weight effects, but confirmatory trials and regulatory review are still underway.
These save with the compound when you add it to My Journal, so they’re on the printout for your visit.
Survodutide is not approved for human use, so DiscoverMedica links to no seller.
We don’t link to sellers of research-only compounds. Products sold “for research use only” are not made for people and are not held to pharmaceutical quality standards.
Educational information only, not medical advice. It does not replace a conversation with a licensed clinician.
A GLP-1 medication that reduces appetite, approved for weight management and type 2 diabetes.
A weekly GIP and GLP-1 medication approved for weight management, sleep apnea and type 2 diabetes.
An older, daily GLP-1 injection for weight management and diabetes, now available as a generic.
A cheap, decades-old diabetes pill that some people ask about for weight and healthy aging.